Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer.

Ekaterina LaukhtinaPaolo GonteroMarko BabjukMarco Moschini Jeremy Yuen Chun TeohMorgan RouprêtQuoc Dien TrinhPiotr ChlostaPéter NyirádyMohammad Abufaraj Shahrokh F ShariatJakob KlemmKensuke Bekku Akihiro MatsukawaShahrokh F Shariat

Published in: BJU international (2024)

In our study, patients with intermediate-risk NMIBC benefit from adjuvant intravesical therapy in terms of RFS. However, in patients without risk factors, adjuvant intravesical therapy did not result in a clear reduction in the recurrence rate.

Keyphrases

muscle invasive bladder cancer
early stage
risk factors
end stage renal disease
ejection fraction
prognostic factors
peritoneal dialysis
smoking cessation